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Abstract
Background:  The cyclooxygenase-2 inhibitor nimesulide is able to reduce kainate-induced
oxidative stress in vivo. Here we investigate if this effect is mediated by the direct antioxidant
properties of nimesulide using a well-characterized in vitro model of kainate toxicity.
Results: Exposure of rat brain homogenates to kainate (12 mM) caused a significant (p < 0.01)
increase in the concentrations of malondialdehyde and 4-hydroxy-alkenals and a significant (p <
0.01) decrease in sulfhydryl levels. High concentrations of nimesulide (0.6–1.6 mM) reduced the
extent of lipid peroxidation and the decline in both total and non-protein sulfhydryl levels induced
by kainate in a concentration-dependent manner.
Conclusions: Our results suggest that the neuroprotective effects of nimesulide against kainate-
induced oxidative stress in vivo are not mediated through its direct free radical scavenging ability
because the concentrations at which nimesulide is able to reduce in vitro kainate excitotoxicity are
excessively higher than those attained in plasma after therapeutic doses.
Background
Nimesulide (N-(4-nitro-2-phenoxy-phenyl)-methanesul-
fonamide) is a non-steroidal anti-inflammatory drug with
potent anti-inflammatory, antipyretic and analgesic prop-
erties which is well tolerated gastrointestinally [1].
Nimesulide is considered a selective cyclooxygenase-2
(COX-2) inhibitor [2,3]. Although inhibition of prosta-
noids synthesis is a key effect of this drug, various non-
prostaglandin mechanisms have been proposed to
explain its mode of action: inhibition of 1) histamine
release and activity [4], 2) cytokine release [5], 3) platelet-
activating factor synthesis [6,7] and 4) phosphodiesterase
type IV activity [9]. Moreover, nimesulide decreases the
production of the superoxide anion (O2•-) by polymor-
phonuclear leukocytes [8,10].
Maffei-Facino and co-workers [11] demonstrated the
direct free radical scavenging activity of nimesulide. In
two different cell free systems, nimesulide acts as a preven-
tive antioxidant by specifically quenching the hydroxyl
radical (HO•), the highly reactive species that, by promot-
ing hydrogen abstraction from polyunsaturated fatty acids
(PUFA), leads to cellular damage mediated by peroxida-
tion of membrane phospholipids.
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Kainic acid (2-carboxy-3-carboxymethyl-4-isoprope-
nylpyrrolidine) is a non-degradable analog of glutamate
isolated from the seaweed Digenea simplex with potent
neuroexcitatory and neurotoxic properties [12]. Those
effects seem to be mediated by a subclass of non-N-
methyl-D-aspartate excitatory amino acid receptors [13].
It was found that free radical generation is associated with
excitatory amino acid-induced brain injury [14]. Kainate
has been shown to generate free radicals when added in
vitro to rat cerebellar cell cultures [15] and in gerbil brain,
following its systemic administration [16]. Also, reactive
oxygen species were detected when kainate was added to
isolated synaptoneurosomes derived from rat cerebral
cortex [17]. Furthermore, it was demonstrated previously
[18] that the addition of kainate to mouse disrupted brain
cells caused a concentration-dependent increase in lipid
peroxidation.
Recently, we have found that kainate-induced excitotoxic-
ity, with the subsequent oxidative damage, is significantly
reduced by the administration of nimesulide at a clinically
relevant dose in the rat hippocampus [19]. In addition, we
also found a marked neuroprotective effect of nimesulide
against hippocampal neuronal damage following global
cerebral ischemic brain damage in gerbils, a type of injury
in which excitotoxicity plays a key role [20].
Given that the effects of nimesulide reducing oxidative
damage in vivo might be attributed to its direct antioxi-
dant properties, the aim of the present study was to deter-
mine whether nimesulide could attenuate the oxidative
damage seen after the in vitro exposure of disrupted brain
cell homogenates to kainate.
Results
The exposure of rat brain homogenates to different con-
centrations of kainate caused a concentration-dependent
increase in the levels of MDA and 4-HDA compared to
those in control samples (Fig. 1). On the other hand, kai-
nate produced a significant decrease in TSH and NPSH
levels, specially the highest concentrations (6 and 12 mM)
as shown in Table 1. Because of the high oxidative damage
induced by 12 mM kainate, this concentration was chosen
for subsequent studies.
When kainate (12 mM) was added to the reaction mixture
together with different concentrations of nimesulide
(ranging from 0.6 to 1.6 mM) the increase in lipid perox-
idation was reduced in a concentration-dependent man-
ner (Fig. 2). In a similar way, nimesulide was able to
protect sulfhydryl groups from kainate-induced oxidative
damage (Table 2). The lowest concentrations of
nimesulide tested (from 0.1 to 0.4 mM) were unable to
confer protection against lipid peroxidation and sulfhy-
dryl groups oxidation as shown in Fig. 2 and Table 2.
We also employed the widely used powerful antioxidant
Trolox C (6-hydroxy-2,5,7,8-tetramethyl-chroman-2-car-
boxilic acid; a water-soluble analogue of α-tocopherol) as
a control and found that Trolox C at concentrations as low
as 50–100 µM was able to significantly (p < 0.05) reduce
oxidative damage induced by 12 mM kainate (data not
shown).
In addition, in the absence of kainate, the exposure of
brain homogenates to the different concentrations of
nimesulide tested did not modify MDA and 4-HDA or
sulfhydryl group levels, which were not significantly
changed as compared to those in control samples (data
not shown).
Discussion
Results from these studies show that kainate-induced oxi-
dative damage as measured by the increase in the concen-
trations of MDA and 4-HDA and by the decrease in
Figure 1
Effect of different concentrations (1, 6 and 12 mM) of kainic 
acid (KA) on malonaldehyde (MDA) and 4-hydroxyalkenals 
(4-HDA) concentrations in perfused rat brain homogenates 
following 20 min incubation. Values are means ± SEM of 3 
experiments. Significant differences were determined by one-
way ANOVA followed by Student-Newman-Keuls post-hoc 
test. *P < 0.05 and **P < 0.01 with respect to control.
Table 1: Effect of different concentrations (1, 6 and 12 mM) of 
kainic acid (KA) on total sulfhydryl groups (TSH) and non-protein 
sulfhydryl groups (NPSH) following 20 min incubation with rat 
brain homogenates.
TSH (nmol/mg protein) NPSH (µmol/g tissue)
Control 23.97 ± 0.25 1.85 ± 0.03
KA (1 mM) 22.97 ± 0.38 1.77 ± 0.05
KA (6 mM) 20.90 ± 0.27 * 1.65 ± 0.05 *
KA (12 mM) 19.25 ± 0.35 ** 1.61 ± 0.04 **
Values are means ± SEM of 3 experiments. *P < 0.05 and **P < 0.01 
with respect to control.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/7
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sulfhydryl groups levels in disrupted cell homogenates
from rat brain is markedly inhibited by high concentra-
tions of nimesulide.
Brain cells are at particular risk from free radical damage
because of their high content of iron and PUFA, the latter
being a substrate for lipid peroxidation, and because of
their relatively deficient antioxidant defense mechanisms
[21].
Our results are consistent with previous reports which
show that kainate-induced death of cerebellar neurons is
prevented either by inhibiting the enzyme xanthine oxi-
dase, a cellular source of superoxide anions, or by the
addition of free radical scavengers to the culture medium
[15]. The generation of free radicals by kainic acid and its
correlation with excitotoxicity have been proposed by sev-
eral groups [15,16,18,22]. The ability of kainate to induce
lipid peroxidation was proven in brain by measuring the
change in conjugated diene and lipid hydroperoxide con-
centrations after exposure of cerebellar granular cells to
the excitotoxin [22]. Furthermore, the addition of kainate
to mouse disrupted brain cells has been shown to cause a
concentration-related increase in thiobarbituric acid-reac-
tive substances generation [18].
It is generally accepted that neuronal degeneration after
kainic acid administration is associated with a depletion
of ATP levels and accumulation of [Ca2+]i . The increase in
[Ca2+]i may trigger Ca2+-activated protease to convert xan-
thine dehydrogenase to xanthine oxidase with the simul-
taneous formation of free radicals [15]. In addition,
xanthine dehydrogenase could be converted to xanthine
oxidase by sulfhydryl oxidation [23]. On the other hand,
the increase in [Ca2+]i may activate enzymes such as phos-
pholipase A2 which hydrolyzes the membrane phosphol-
ipids to release PUFA leading to free radical generation
[15].
In our previous study we found a significant neuroprotec-
tive effect of the cyclooxygenase-2 inhibitor nimesulide
against the depletion of reduced glutathione and increase
in lipid peroxidation at a therapeutically relevant dose (6
mg/kg; i.p) [19]. Similarly, in the present study
nimesulide was able to protect against in vitro kainate-
induced sulfhydryl group oxidation and lipid peroxida-
tion, but this effect was observed only at high concentra-
tions, which are unlikely to be attained in plasma after
therapeutic doses. Even when the effects of nimesulide
against kainate excitotoxicity in vivo and in vitro are sim-
ilar, the mechanisms of nimesulide neuroprotection in
vivo are quite different from the in vitro effects on meas-
ures of oxidative injury, because in the in vitro model
(homogenates of rat brain), nimesulide might be acting
directly as a scavenger of kainate-generated reactive
oxygen species, producing a concomitant reduction in
markers of oxidative stress. Unlike the in vitro situation,
nimesulide treatment afforded a neuroprotective effect
against kainate-induced in vivo oxidative stress in the rat
hippocampus, probably acting through inhibition of
cyclooxygenase-2, which is now considered a key cellular
source of free radicals in the injured brain [24]. It is
important to emphasize that several studies have found a
marked expression of cerebral cyclooxygenase-2 mRNA
and protein following the systemic administration of kai-
Figure 2
Effect of Nimesulide (NIM) on malonaldehyde (MDA) and 4-
hydroxy-alkenals (4-HDA) concentrations in perfused rat 
brain homogenates following 20 min incubation with 12 mM 
kainic acid (KA). Values are means ± SEM of 3 experiments. 
Significant differences were determined by one-way ANOVA 
followed by Student-Newman-Keuls post-hoc test. *P < 0.05 
and **P < 0.01 with respect to KA 12 mM.
Table 2: Effect of nimesulide (NIM) on total sulfhydryl groups 
(TSH) and non-protein sulfhydryl groups (NPSH) following 20 
min incubation with 12 mM kainic acid (KA).
TSH (nmol/mg protein) NPSH (µmol/g tissue)
Control 23.97 ± 0.25 ** 1.85 ± 0.03 **
KA 19.25 ± 0.35 1.61 ± 0.04
KA + NIM (0.1 mM) 18.72 ± 0.38 1.57 ± 0.03
KA + NIM (0.2 mM) 20.21 ± 0.56 1.64 ± 0.03
KA + NIM (0.4 mM) 20.25 ± 0.35 1.71 ± 0.02
KA + NIM (0.6 mM) 21.96 ± 0.46 * 1.76 ± 0.03 *
KA + NIM (0.8 mM) 22.67 ± 0.30 ** 1.76 ± 0.01 *
KA + NIM (1.0 mM) 23.14 ± 0.15 ** 1.78 ± 0.02 *
KA + NIM (1.2 mM) 23.03 ± 0.30 ** 1.81 ± 0.04 **
KA + NIM (1.4 mM) 23.68 ± 0.25 ** 1.79 ± 0.03 **
KA + NIM (1.6 mM) 24.03 ± 0.31 ** 1.81 ± 0.02 **
Values are means ± SEM of 3 experiments. Significant differences 
were determined by one-way ANOVA followed by Student-Newman-
Keuls post-hoc test: *P < 0.05 and **P < 0.01 with respect to KA 12 
mM.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/7
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nate [25–27]. The induction of cyclooxygenase-2 expres-
sion parallels the appearance of neuronal apoptotic
features in cell types affected by kainate, and excitotoxic
neuronal death in vitro is accompanied by a selective ele-
vation in cyclooxygenase-2 mRNA, indicating that
cyclooxygenase-2 may be involved in pathways leading to
neuronal death [28]. In support of this, results from our
previous work indicated that the induction of cyclooxyge-
nase-2 is involved in kainate-mediated free radicals for-
mation [19]. Based on the pharmacological effects of
nimesulide, additional mechanisms could account for the
neuroprotection conferred by nimesulide against in vivo
kainate excitotoxicity, such as inhibition of pro-inflam-
matory cytokines production, reduction in nitric oxide
generation and blockade of apoptotic pathways, but these
effects should be confirmed.
Several findings support the antioxidant activity of
nimesulide [11,29,30]. Using the in vitro model of
NADPH-supported lipid peroxidation in rat liver micro-
somes, nimesulide and its metabolites significantly inhib-
ited MDA formation in a concentration-dependent
manner [29]. Furthermore, using an in vitro assay based
on the oxidation of phosphatidylcholine liposomes
(exposed to a flux of hydroxyl radicals generated by water
sonolysis), nimesulide exhibited a remarkable scavenging
activity against free radicals at concentrations easily
attainable in vivo (4.92 µM). Maffei-Facino and co-work-
ers [11] investigated the superoxide anion (O2•-) and
hydroxyl radical (HO•) scavenging activities of
nimesulide and its main metabolite 4-hydroxy-
nimesulide, using the Electron Spin Resonance (ESR)
spectroscopy with the spin trapping technique. According
to their results, 4-hydroxy-nimesulide is a good scavenger
of both oxygen free radicals and its rate constant of reac-
tion with HO• is 8.9 × 1010 M-1 s-1 . Nimesulide, which has
been shown by ESR to be inactive as a O2•- quencher, has
a rate constant of reaction with HO• slightly greater than
that of its metabolite (3.3 × 1011 M-1 s-1). Taken together,
all these studies indicate that antioxidant properties might
account for the pharmacological effects of nimesulide.
In the present study, nimesulide conferred a concentra-
tion-dependent protection against kainate-induced
peroxidation of membrane phospholipids when added
together with kainate. The lowest concentrations of
nimesulide (0.1 to 0.4 mM) were unable to reduce lipid
peroxidation (Fig. 2). Similarly, only the highest concen-
trations of nimesulide (from 0.6 to 1.6 mM) were able to
protect sulfhydryl groups from oxidation, suggesting that
relatively high concentrations of nimesulide are able to
protect against in vitro kainate toxicity.
Conclusions
In summary, since the concentrations of nimesulide in
plasma are estimated to be around 10–20 µM after the
administration of clinically used doses [3], results from
the present study suggest that the in vivo neuroprotective
effects of nimesulide against kainate excitotoxicity are not
mediated by direct free radical scavenging ability of this
compound because only excessively high concentrations
(0.6–1.6 mM) were proven to reduce kainate-induced oxi-
dative stress in our study. It is much more likely that the
effects of nimesulide against kainate-induced oxidative
damage [19] are mediated by the inhibition of cyclooxy-
genase-2, a key source of free radicals under damaging
conditions to the brain [24].
Methods
Chemicals
All reagents were of the highest quality available. Kainic
acid and 5,5'-dithiobis-(2-nitrobenzoic acid) were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
Nimesulide was kindly provided by Gautier-Bagó Labora-
tories (Buenos Aires, Argentina). The Bioxytech LPO-586
kit for lipid peroxidation was obtained from Cayman
Chemical Co. (Ann Arbor, MI, USA).
Animals
Adult male Sprague-Dawley rats (body weight 200–250 g;
n = 12) were obtained from CENPALAB (Havana, Cuba)
and housed in Plexiglass cages (4 per cage) and main-
tained in an air-filtered and automatic temperature con-
trolled (20–22°C) room with a relative humidity of 50–
52%. Rats were fed with standard laboratory chow and
water ad libitum and were kept under artificial light-dark
cycle of 12 h.
Solutions and range of concentrations
Nimesulide was dissolved in absolute ethanol (when
added to the brain homogenate, the final alcohol concen-
tration was 1%) and added as one of nine different con-
centrations (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, and 1.6
mM) to the incubation mixture. The exposure of rat brain
homogenates to 1% ethanol was proven not to produce
any effect [31]. Kainic acid was dissolved in Tris-HCl
buffer (20 mM, pH 7.4) and added in 3 different concen-
trations (1, 6 and 12 mM) to the homogenate.
Brain sample preparation
Rats were anesthetized with diethyl ether and subjected to
intracardiac perfusion using a peristaltic pump (DIDT-
CNIC Peristaltic, Cuba) with ice-cold saline in order to
eliminate the excess of iron (bound to hemoglobin) that
may artificially increase free radical generation. Brains
were collected and immediately stored at -70°C.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/7
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Lipid peroxidation assay
This assay was conducted as previously reported [31].
Briefly, twelve brains were pooled and homogenized in
ice-cold Tris-HCl buffer (20 mM, pH 7.4) with a motor
driven homogenizer (Edmund Bühler, Germany) to pro-
duce a 1/10 homogenate. Aliquots of the homogenates
were incubated in a shaking water bath for 20 min at
37°C with different concentrations of kainic acid and
with or without nine different concentrations of
nimesulide (from 0.1 to 1.6 mM). Moreover, nimesulide
(at the concentrations tested) was added to the homoge-
nate without kainate. After the incubation time, the reac-
tion was stopped by cooling the samples in ice for 10 min.
Thereafter, the samples were centrifuged at 12 000 × g for
5 min. The supernatant was collected and immediately
tested for lipid peroxidation and sulfhydryl groups.
Lipid peroxidation was assessed by measuring the concen-
tration of malonaldehyde (MDA) and 4-hydroxy-alkenals
(4-HDA). These constituents are formed, for the most
part, from the peroxidation of PUFA and are widely used
as an index of lipid peroxidation [32]. The Bioxytech LPO-
586 kit was used for these measurements; this kit takes
advantage of a chromogenic reagent (N-methyl-2-phe-
nylindole) which reacts with MDA and 4-HDA at 45°C
yielding a stable chromophore with maximal absorbance
at a wavelength of 586 nm. This wavelength and the low
temperature of incubation used in this procedure mini-
mize interferences and undesirable artifacts [32].
Sulfhydryl groups assay
Total (TSH) and non-protein (NPSH) sulfhydryl groups
determinations were performed according to the method
of Sedlak and Lindsay [33] using the Ellman's reagent.
Protein assay
Total protein concentration was determined using the
Coomassie Blue method [34] with bovine serum albumin
as standard.
Statistical analysis
Results are presented as mean ± SEM (standard error of
means). All data were analyzed by one-way analysis of
variance (ANOVA). If the F values were significant, the
Student-Newman-Keuls post-hoc test was used to com-
pare groups. The level of significance was accepted at
p<0.05.
List of Abbreviations
O2•-, superoxide anion; HO•, hydroxyl radical; PUFA,
polyunsaturated fatty acids; MDA, malonaldehyde; 4-
HDA, 4-hydroxy-alkenals; TSH, total sulfhydryl groups;
NPSH, non-protein sulfhydryl groups; COX-2,
cyclooxygenase-2.
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